Mats Thorén

Mats Thorén has 25 years of experience in the financial markets, where he has worked in Healthcare both as an equity analyst and in corporate finance. For the past seventeen years, Mats Thorén has been a Healthcare investment professional. He has worked with Nalka Life Science AB and MedCap AB and now manages his own company, Vixco Capital, with a focus on investments. He currently serves on the boards of Xbrane BioPharma AB (Stockholm Smallcap), Arcoma AB (Stockholm First North), and Herantis Pharma Oy (Stockholm and Helsinki First North). He has previous board experience from C-Rad AB (Stockholm First North), as well as Cellartis AB, Duocort AB, MIP Technologies AB, and several other private companies. Mats Thorén has studied at the Stockholm School of Economics focusing on Accounting and Financial Economics as well as studied medicine at the Karolinska Institute in Stockholm.